A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Enzo Biochem Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 34,000 shares of ENZ stock, worth $39,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,000
Holding current value
$39,440
% of portfolio
0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$1.3 - $1.87 $1,674 - $2,408
1,288 Added 21.3%
7,334 $10,000
Q2 2023

Aug 14, 2023

SELL
$1.84 - $2.66 $30,980 - $44,786
-16,837 Reduced 73.58%
6,046 $11,000
Q1 2023

May 15, 2023

SELL
$1.0 - $2.51 $39,893 - $100,131
-39,893 Reduced 63.55%
22,883 $55,000
Q4 2022

Feb 14, 2023

BUY
$1.16 - $2.42 $51,718 - $107,895
44,585 Added 245.09%
62,776 $89,000
Q3 2022

Nov 14, 2022

SELL
$2.1 - $2.73 $21,575 - $28,048
-10,274 Reduced 36.09%
18,191 $40,000
Q2 2022

Aug 15, 2022

BUY
$2.0 - $3.0 $35,926 - $53,889
17,963 Added 171.04%
28,465 $59,000
Q1 2022

May 16, 2022

SELL
$2.9 - $3.47 $11,826 - $14,150
-4,078 Reduced 27.97%
10,502 $30,000
Q4 2021

Feb 14, 2022

SELL
$3.17 - $4.09 $127,963 - $165,101
-40,367 Reduced 73.47%
14,580 $46,000
Q3 2021

Nov 15, 2021

SELL
$3.01 - $3.77 $56,777 - $71,113
-18,863 Reduced 25.56%
54,947 $195,000
Q2 2021

Aug 16, 2021

BUY
$2.86 - $3.61 $82,962 - $104,718
29,008 Added 64.75%
73,810 $233,000
Q1 2021

May 17, 2021

BUY
$2.61 - $4.08 $45,327 - $70,857
17,367 Added 63.3%
44,802 $154,000
Q4 2020

Feb 16, 2021

SELL
$1.82 - $2.61 $42,975 - $61,629
-23,613 Reduced 46.26%
27,435 $69,000
Q3 2020

Nov 16, 2020

SELL
$2.02 - $3.02 $96,287 - $143,954
-47,667 Reduced 48.29%
51,048 $107,000
Q1 2020

May 15, 2020

BUY
$1.82 - $3.87 $61,374 - $130,504
33,722 Added 51.89%
98,715 $250,000
Q4 2019

Feb 14, 2020

SELL
$2.57 - $3.68 $137,554 - $196,964
-53,523 Reduced 45.16%
64,993 $171,000
Q3 2019

Nov 14, 2019

BUY
$3.01 - $4.0 $95,862 - $127,392
31,848 Added 36.75%
118,516 $426,000
Q2 2019

Aug 14, 2019

BUY
$2.79 - $4.31 $80,686 - $124,645
28,920 Added 50.08%
86,668 $292,000
Q1 2019

May 15, 2019

SELL
$2.54 - $4.02 $11,894 - $18,825
-4,683 Reduced 7.5%
57,748 $0
Q4 2018

Feb 14, 2019

SELL
$2.46 - $4.2 $76,004 - $129,763
-30,896 Reduced 33.11%
62,431 $173,000
Q3 2018

Nov 13, 2018

SELL
$3.81 - $5.53 $8,210 - $11,917
-2,155 Reduced 2.26%
93,327 $0
Q2 2018

Aug 10, 2018

SELL
$5.06 - $6.78 $13,145 - $17,614
-2,598 Reduced 2.65%
95,482 $0
Q1 2018

May 11, 2018

BUY
$5.43 - $8.36 $227,185 - $349,774
41,839 Added 74.39%
98,080 $538,000
Q4 2017

Feb 09, 2018

BUY
$8.15 - $10.55 $355,975 - $460,802
43,678 Added 347.67%
56,241 $458,000
Q3 2017

Nov 09, 2017

BUY
$10.45 - $11.44 $131,283 - $143,720
12,563
12,563 $132,000

Others Institutions Holding ENZ

About ENZO BIOCHEM INC


  • Ticker ENZ
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 48,720,500
  • Market Cap $56.5M
  • Description
  • Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. Th...
More about ENZ
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.